Stroke prevention in atrial fibrillation: An Asian perspective

Chern-En Chiang; Kang-Ling Wang; Gregory Y. H. Lip

doi:10.1160/TH13-11-0948

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2014; 111(05): 789-797
DOI: 10.1160/TH13-11-0948

Theme Issue Article

Schattauer GmbH

Stroke prevention in atrial fibrillation: An Asian perspective

Chern-En Chiang

¹General Clinical Research Center and Division of Cardiology, Taipei Veterans General Hospital and National Yang-Ming University, Taipei, Taiwan

,

Kang-Ling Wang

¹General Clinical Research Center and Division of Cardiology, Taipei Veterans General Hospital and National Yang-Ming University, Taipei, Taiwan

,

Gregory Y. H. Lip

²University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, UK

› Institutsangaben

Abstract

Summary

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia. In 2050, it is estimated that there will be 72 million AF patients in Asia, accounting for almost 2.9 million patients suffering from AF-associated stroke. Asian AF patients share similar risk factor profiles as non-Asians, except that more Asians have a history of previous stroke. Clinical challenges are evident in the field of stroke prevention in AF, amongst Asians. Existing stroke and bleeding risk scores have not been well-validated in Asians. Asians are prone to bleeding when treated with warfarin, and the optimal international normalised ratio (INR) for warfarin use is yet to be determined in Asians, though Asian physicians tend to keep it in a lower range (e.g. INR 1.6–2.6) for elderly patients despite limited evidence to justify this. In general, warfarin is ‘difficult’ to use in Asians due to higher risk of bleeding and higher stroke rate in Asians than in non-Asians, as shown in randomised controlled trials. Excess of bleeding was not found in Asians when novel oral anticoagulants (NOACs) were used. Besides, the superiority of NOACs to warfarin in reducing thromboembolism was maintained in Asians. Therefore NOACs are preferentially indicated in Asians in terms of both efficacy and safety. Also, some preliminary data suggest that Asian patients with AF might not be the same. Future prospective randomised trials are needed for the selection of NOACs according to different ethnic background.

Note: The review process for this manuscript was fully handled by Christian Weber, Editor in Chief.

Keywords

Atrial fibrillation - Asians - major bleeding - novel oral anticoagulants - stroke

Volltext

Referenzen

References
1 Chiang CE, Zhang S, Tse HF. et al. Atrial fibrillation management in Asia: From the Asian expert forum on atrial fibrillation. Int J Cardiol 2013; 164: 21-32.
2 Go AS, Hylek EM, Phillips KA. et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. J Am Med Assoc 2001; 285: 2370-2375.
3 Lip GY, Brechin CM, Lane DA. The global burden of atrial fibrillation and stroke: a systematic review of the epidemiology of atrial fibrillation in regions outside North America and Europe. Chest 2012; 142: 1489-1498.
4 Tse HF, Wang YJ, Ahmed Ai-Abdullah M. et al. Stroke prevention in atrial fibrillation-An Asian stroke perspective. Heart Rhythm 2013; 10: 1082-1088.
5 Miyasaka Y, Barnes ME, Gersh BJ. et al. Secular Trends in Incidence of Atrial Fibrillation in Olmsted County, Minnesota, 1980 to 2000, and Implications on the Projections for Future Prevalence. Circulation 2006; 114: 119-125.
6 Krijthe BP, Kunst A, Benjamin EJ. et al. Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060. Eur Heart J 2013; 34: 2746-2751.
7 Chiang CE, Wang KL, Naditch-Brule L. et al. Complexity of atrial fibrillation in Chinese in routine daily practice: insights from the REALISEAF-Taiwan registry. Pacing Clin Electrophysiol 2011; 34: 1310.
8 Akao M, Chun YH, Wada H. et al. Current status of clinical background of patients with atrial fibrillation in a community-based survey: the Fushimi AF Registry. J Cardiol 2013; 61: 260-266.
9 Guo Y, Apostolakis S, Blann AD. et al. Validation of contemporary stroke and bleeding risk stratification scores in non-anticoagulated Chinese patients with atrial fibrillation. Int J Cardiol 2013; 168: 904-909.
10 Gage BF, Waterman AD, Shannon W. et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. J Am Med Assoc 2001; 285: 2864-2870.
11 Nieuwlaat R, Capucci A, Camm AJ. et al. Atrial fibrillation management: a prospective survey in ESC Member Countries. Eur Heart J 2005; 26: 2422-2434.
12 Le Heuzey JY, Breithardt G, Camm J. et al. The RecordAF study: design, baseline data, and profile of patients according to chosen treatment strategy for atrial fibrillation. Am J Cardiol 2010; 105: 687-693.
13 Amerena J, Chen SA, Sriratanasathavorn C. et al. Insights into management of atrial fibrillation in Asia Pacific gained from baseline data from REgistry on cardiac rhythm disORDers (RecordAF-Asia Pacific [AP]) registry. Am J Cardiol 2012; 109: 378-382.
14 Steg PG, Alam S, Chiang CE. et al. Symptoms, functional status and quality of life in patients with controlled and uncontrolled atrial fibrillation: data from the RealiseAF cross-sectional international registry. Heart 2012; 98: 195-201.
15 Connolly SJ, Ezekowitz MD, Yusuf S. et al. Dabigatran versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med 2009; 361: 1139-1151.
16 Hori M, Connolly SJ, Zhu J. et al. Dabigatran Versus Warfarin: Effects on Ischaemic and Haemorrhagic Strokes and Bleeding in Asians and Non-Asians With Atrial Fibrillation. Stroke 2013; 44: 1891-1896.
17 Patel MR, Mahaffey KW, Garg J. et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883-891.
18 Granger CB, Alexander JH, McMurray JJ. et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981-992.
19 Goto S, Zhu J, Lisheng L. et al. Efficacy and safety of apixaban compared with warfarin for stroke prevention in atrial fibrillation in East Asia. Eur Heart J 2013; 34 (Abstract Supplement): 1039.
20 Rietbrock S, Heeley E, Plumb J. et al. Chronic atrial fibrillation: Incidence, prevalence, and prediction of stroke using the Congestive heart failure, Hypertension, Age >75, Diabetes mellitus, and prior Stroke or transient ischaemic attack (CHADS2) risk stratification scheme. Am Heart J 2008; 156: 57-64.
21 Komatsu T, Tachibana H, Sato Y. et al. Relationship between CHADS2 score and ischaemic stroke during rhythm control therapy for paroxysmal atrial fibrillation. Int Heart J 2010; 51: 24-29.
22 Keogh C, Wallace E, Dillon C. et al. Validation of the CHADS2 clinical prediction rule to predict ischaemic stroke. A systematic review and meta-analysis. Thromb Haemost 2011; 106: 528-538.
23 Lip GY, Nieuwlaat R, Pisters R. et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 2010; 137: 263-272.
24 Olesen JB, Torp-Pedersen C, Hansen ML. et al. The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: a nationwide cohort study. Thromb Haemost 2012; 107: 1172-1179.
25 Coppens M, Eikelboom JW, Hart RG. et al. The CHA2DS2-VASc score identifies those patients with atrial fibrillation and a CHADS2 score of 1 who are unlikely to benefit from oral anticoagulant therapy. Eur Heart J 2013; 34: 170-176.
26 Ogawa S, Aonuma K, Tse HF. et al. The APHRS’s 2013 statement on antithrombotic therapy of patients wiht nonvalvular atrial fibrillation. J Arrhythm 2013; 29: 190-200.
27 Lin LY, Lee CH, Yu CC. et al. Risk factors and incidence of ischaemic stroke in Taiwanese with nonvalvular atrial fibrillation-- a nation wide database analysis. Atherosclerosis 2011; 217: 292-295.
28 Gallagher AM, Setakis E, Plumb JM. et al. Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients. Thromb Haemost 2011; 106: 968-977.
29 Gallego P, Roldan V, Marin F. et al. Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation. Thromb Haemost 2013; 110: 1189-1198.
30 Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994; 154: 1449-1457.
31 Hart RG, Pearce LA, McBride R. et al. Factors associated with ischaemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials. The Stroke Prevention in Atrial Fibrillation (SPAF) Investigators. Stroke 1999; 30: 1223-1229.
32 Hylek EM, Skates SJ, Sheehan MA. et al. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med 1996; 335: 540-546.
33 Hylek EM, Go AS, Chang Y. et al. Effect of Intensity of Oral Anticoagulation on Stroke Severity and Mortality in Atrial Fibrillation. N Engl J Med 2003; 349: 1019-1026.
34 You JH, Chan FW, Wong RS. et al. Is INR between 2.0 and 3.0 the optimal level for Chinese patients on warfarin therapy for moderate-intensity anticoagulation?. Br J Clin Pharmacol 2005; 59: 582-587.
35 Suzuki S, Yamashita T, Kato T. et al. Incidence of Major Bleeding Complication of Warfarin Therapy in Japanese Patients With Atrial Fibrillation. Circulation J 2007; 71: 761-765.
36 Yamaguchi T. Group fJNAFESPCS. Optimal Intensity of Warfarin Therapy for Secondary Prevention of Stroke in Patients with Nonvalvular Atrial Fibrillation: A Multicenter, Prospective, Randomized Trial. Stroke 2000; 31: 817-821.
37 Group JCSJW. Guidelines for Pharmacotherapy of Atrial Fibrillation (JCS 2008) - Digest Version. Circulation J 2010; 74: 2479-2500.
38 Yasaka M, Minematsu K, Yamaguchi T. Optimal intensity of international normalized ratio in warfarin therapy for secondary prevention of stroke in patients with non-valvular atrial fibrillation. Intern Med 2001; 40: 1183-1188.
39 Inoue H, Okumura K, Atarashi H. et al. Target international normalized ratio values for preventing thromboembolic and haemorrhagic events in Japanese patients with non-valvular atrial fibrillation: results of the J-RHYTHM Registry. Circ J 2013; 77: 2264-2270.
40 Shen AY, Yao JF, Brar SS. et al. Racial/ethnic differences in the risk of intracran-ial haemorrhage among patients with atrial fibrillation. J Am Coll Cardiol 2007; 50: 309-315.
41 Wang KL, Chiang CE. Optimal international normalized ratio for atrial fibrillation in asians and Japanese. Circ J 2013; 77: 2242-2243.
42 van Asch CJ, Luitse MJ, Rinkel GJ. et al. Incidence, case fatality, and functional outcome of intracerebral haemorrhage over time, according to age, sex, and ethnic origin: a systematic review and meta-analysis. Lancet Neurol 2010; 09: 167-176.
43 Takahashi H, Wilkinson GR, Caraco Y. et al. Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients. Clin Pharmacol Ther 2003; 73: 253-263.
44 Rieder MJ, Reiner AP, Gage BF. et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005; 352: 2285-2293.
45 Lip GY, Lin HJ, Hsu HC. et al. Comparative assessment of the HAS-BLED score with other published bleeding risk scoring schemes, for intracranial haemorrhage risk in a non-atrial fibrillation population: the Chin-Shan Community Cohort Study. Int J Cardiol 2013; 168: 1832-1836.
46 Apostolakis S, Lane DA, Buller H. et al. Comparison of the CHADS2, CHA2DS2-VASc and HAS-BLED scores for the prediction of clinically relevant bleeding in anticoagulated patients with atrial fibrillation: The AMADEUS trial. Thromb Haemost 2013; 110: 1074-1079.
47 Roldan V, Marin F, Manzano-Fernandez S. et al. The HAS-BLED Score Has Better Prediction Accuracy for Major Bleeding Than CHADS2 or CHA2DS2-VASc Scores in Anticoagulated Patients With Atrial Fibrillation. J Am Coll Cardiol 2013; 62: 2199-2204.
48 Albertsen IE, Rasmussen LH, Overvad TF. et al. Risk of Stroke or Systemic Embolism in Atrial Fibrillation Patients Treated With Warfarin: A Systematic Review and Meta-analysis. Stroke 2013; 44: 1329-1336.
49 Wan Y, Heneghan C, Perera R. et al. Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review. Circ Cardiovasc Qual Outcomes 2008; 01: 84-91.
50 Apostolakis S, Sullivan RM, Olshansky B. et al. Factors Affecting Quality of Anticoagulation Control Among Patients With Atrial Fibrillation on Warfarin: The SAMe-TT2R2 Score. Chest 2013; 144: 1555-1563.
51 De Caterina R, Husted S, Wallentin L. et al. General mechanisms of coagulation and targets of anticoagulants (Section I). Position Paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease. Thromb Haemost 2013; 109: 569-579.
52 De Caterina R, Husted S, Wallentin L. et al. Vitamin K antagonists in heart disease: Current status and perspectives (Section III). Position Paper of the ESC Working Group on Thrombosis - Task Force on Anticoagulants in Heart Disease. Thromb Haemost 2013; 110: 1087-1107.
53 Pisters R, Nieuwlaat R, Lane DA. et al. Potential net clinical benefit of population-wide implementation of apixaban and dabigatran among European patients with atrial fibrillation. A modelling analysis from the Euro Heart Survey. Thromb Haemost 2013; 109: 328-336.
54 Guo Y, Pisters R, Apostolakis S. et al. Stroke risk and suboptimal thromboprophylaxis in Chinese patients with atrial fibrillation: would the novel oral anticoagulants have an impact?. Int J Cardiol 2013; 168: 515-522.